A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention

Journal of Medical Economics
Lieven AnnemansHéctor Bueno

Abstract

The aim of this narrative review was to summarise the cost analyses and supporting trial data for aspirin prophylaxis in primary prevention. A PubMed search using the term 'aspirin and cost-effective and primary prevention' was performed. Professional meetings (2009) were also searched for any relevant abstracts contacting the terms 'aspirin' and 'cost effectiveness'. Where possible, outcomes were discussed in terms of cost implications (expressed as quality-adjusted life-year [QALY], disability-adjusted life-year or incremental cost-effectiveness ratio) in relation to the annual risk of cardiovascular disease. Aspirin was included in cost-effectiveness models that determined direct cost savings. A total of 67 papers were identified using PubMed, and 17 cost-effectiveness studies, which assessed aspirin in primary prevention (largely based on the key primary prevention studies), and two abstracts were included in the review. These analyses showed that low-dose aspirin was cost effective in a variety of scenarios. In the UK, Germany, Spain, Italy and Japan, the mean 10-year direct cost saving (including follow-up costs and aspirin costs) per patient was €201, €281, €797, €427 and €889 with aspirin use in patients with an annual ...Continue Reading

References

Jan 30, 1988·British Medical Journal·R PetoS Norton
Mar 9, 2005·The New England Journal of Medicine·Paul M RidkerJulie E Buring
Jan 19, 2006·JAMA : the Journal of the American Medical Association·Jeffrey S BergerDavid L Brown
Feb 24, 2006·European Heart Journal·José LealMike Rayner
May 17, 2006·Heart·R Luengo-FernándezM Rayner
Jul 29, 2006·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Tom Marshall
Aug 31, 2006·International Journal of Clinical Practice·L AnnemansF W A Verheugt
Sep 5, 2006·The American Journal of Cardiology·Alfred A Bartolucci, George Howard
Jan 20, 2007·International Journal of Technology Assessment in Health Care·Oscar H FrancoLuc Bonneux
Feb 14, 2007·Archives of Internal Medicine·Michael PignoneJeffrey A Tice
Feb 24, 2007·Cost Effectiveness and Resource Allocation : C/E·Bjarne RobberstadOle F Norheim
Sep 18, 2007·Alimentary Pharmacology & Therapeutics·M E Sartore, K M Kamal
Oct 15, 2008·Arquivos brasileiros de cardiologia·José Ramos FilhoEloá Jacinto Lima
Nov 11, 2008·JAMA : the Journal of the American Medical Association·Hisao OgawaUNKNOWN Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators
Dec 17, 2008·Circulation·Donald Lloyd-JonesUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
May 7, 2009·The Canadian Journal of Cardiology·Nadia A KhanUNKNOWN Canadian Hypertension Education Program
Jun 2, 2009·Lancet·Ale Algra, Jacoba P Greving
Oct 20, 2009·Journal of Hypertension·Giuseppe ManciaUNKNOWN European Society of Hypertension
Oct 27, 2009·Diabetes Research and Clinical Practice·Chunyu ZhangJunbo Ge
Jan 29, 2010·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Jan 15, 2015·Revista Española De Cardiología·Enrique GalveJosé Ramón González-Juanatey
Apr 27, 2011·Expert Review of Cardiovascular Therapy·Andrew BivardMark W Parsons
Nov 21, 2017·International Heart Journal·Satoshi KoderaIssei Komuro

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.